Verona Pharma PLC American Depositary Share (VRNA) to Release Earnings on Thursday

Key Points

• Verona Pharma PLC is set to release its Q2 2025 earnings on Thursday, August 14th, with analysts expecting earnings of $0.39 per share and revenue of $68.24 million.
• The company's shares have recently experienced changes in analyst ratings, with several firms downgrading them from a "strong-buy" to a "hold" rating, and an average target price of $109.00.
• Insiders have sold significant amounts of stock recently, with CFO Mark W. Hahn selling 400,000 shares valued at approximately $4.56 million, representing a decrease in their ownership position by 3.15%.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of $0.39 per share and revenue of $68.24 million for the quarter.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.14. On average, analysts expect Verona Pharma PLC American Depositary Share to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Verona Pharma PLC American Depositary Share Stock Down 0.0%

Shares of NASDAQ:VRNA opened at $105.39 on Thursday. Verona Pharma PLC American Depositary Share has a 52-week low of $19.45 and a 52-week high of $105.50. The stock has a market cap of $8.97 billion, a P/E ratio of -52.70 and a beta of 0.12. The business has a fifty day moving average of $95.52 and a two-hundred day moving average of $74.60. The company has a quick ratio of 8.73, a current ratio of 8.86 and a debt-to-equity ratio of 1.07.

Analyst Ratings Changes

VRNA has been the subject of several research reports. Truist Financial downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Wednesday, July 9th. Canaccord Genuity Group cut Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and set a $107.00 target price for the company. in a report on Wednesday, July 9th. TD Cowen cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 9th. Wolfe Research lowered shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 10th. Finally, Jefferies Financial Group reaffirmed a "hold" rating and set a $107.00 target price (down from $140.00) on shares of Verona Pharma PLC American Depositary Share in a research note on Wednesday, July 9th. Eleven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, Verona Pharma PLC American Depositary Share has an average rating of "Hold" and an average target price of $109.00.

Insiders Place Their Bets

In other news, CFO Mark W. Hahn sold 400,000 shares of the firm's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total value of $4,560,000.00. Following the transaction, the chief financial officer directly owned 12,278,992 shares in the company, valued at approximately $139,980,508.80. This trade represents a 3.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Kathleen A. Rickard sold 58,336 shares of the company's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $13.14, for a total value of $766,535.04. Following the transaction, the insider directly owned 2,607,472 shares of the company's stock, valued at $34,262,182.08. This trade represents a 2.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,220,584 shares of company stock worth $24,613,268. 4.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. lifted its holdings in shares of Verona Pharma PLC American Depositary Share by 44.2% in the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after buying an additional 193 shares during the period. Acadian Asset Management LLC bought a new position in shares of Verona Pharma PLC American Depositary Share during the 1st quarter valued at about $48,000. NewEdge Advisors LLC acquired a new position in shares of Verona Pharma PLC American Depositary Share in the 1st quarter worth approximately $58,000. Royal Bank of Canada raised its holdings in shares of Verona Pharma PLC American Depositary Share by 43.3% in the 1st quarter. Royal Bank of Canada now owns 9,719 shares of the company's stock worth $617,000 after purchasing an additional 2,938 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Verona Pharma PLC American Depositary Share by 274.5% during the first quarter. Goldman Sachs Group Inc. now owns 1,041,408 shares of the company's stock valued at $66,119,000 after purchasing an additional 763,353 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.